A Review on Corona Virus and Covid-19

1*Vivek Kumar, 2, Km. Monika, 3Rajkumar Bharti, 4Najam Ali Khan.

1MET Faculty of Pharmacy, Moradabad-244001(U.P.), India.
2RGIP Chandausi Moradabad -244001(U.P.), India.
3,4School of Pharmaceutical Sciences, IFTM University, Lodhipur Rajput, Moradabad, India.
4*Corresponding author’s E-mail: vivekkumarbph1@gmail.com

Received: 12-08-2020; Revised: 15-10-2020; Accepted: 23-10-2020; Published on: 15-11-2020.

ABSTRACT

Covid-19, the pandemic disease brought about by SARS-CoV-2. It is an intense infection contamination. SARS-CoV-2 is a positive-sense, single-stranded RNA virus. This infection influences the nose, eyes, respiratory parcel, lungs and so on of the patients. In view of the momentum research proof it is recognized the transmission of SARS-CoV-2 happens generally individual to individual through respiratory droplets inside a scope of 180 cm. The infection can likewise be communicated if an individual contacts a mucosal surface subsequent to contacting an article with the infection on it. The World Health Organization (WHO) has announced the progressing flare-up to be a worldwide general wellbeing crisis. Since there is not precise treatment and antibody for the treatment of Covid-19. Be that as it may, an enemy of malarial medication hydroxychloroquin now a day utilized in the treatment of Covid-19. Genomic correlation has demonstrated that the SARS-CoV-2 has 80% similarity to Rhinolophus sinicus bat and 96% likeness with the Rhinolophus affinis bat. By finding the current distributed proof, this survey deliberately sums up the study of disease transmission, genomic structure, pathogenic mechanism, clinical quality, method of transmission, treatment and prevention of Covid-19.

Keywords: Covid-19, SARS-CoV-2, WHO, ACE-2, Hydroxychloroquin.

INTRODUCTION

Corona virus were first recognized during the 1960s, nonetheless, we don’t have the foggiest thought where they start from. A CoV might be a sort of normal contamination that causes an ailment in your nose, sinuses, or upper throat.1 Most CoVs are not hazardous. They get their name from their crown-like shape. To a great extent, anyway not often, a CoVs can pollute the two animals and individuals.2 Four CoVs in particular HKU1, NL63, 229E, and OC43 have been available for use in people, and by and large reason me...
**EPIDEMIOLOGY**

As of March 10, 2020, the WHO has revealed that there are 113,702 affirmed cases around the world, and 4012 death have been enrolled; 71% of every affirmed case (80,924) and 78% of all death related with COVID-19 (3140) are from China and its domains. Since the principal detailed case in Wuhan, 109 different nations have pronounced that they have in any event one affirmed instance of COVID-19. The WHO has authoritatively grouped China as an "exceptionally high danger" district for COVID-19.10

**GENETIC STRUCTURE AND PATHOGENIC MECHANISM OF SARS-CoV-2**

Corona virus is a single-stranded RNA virus with a distance across of 80–120 nm. There are four types: α-Corona virus, β-Corona virus, δ-Corona virus and γ-Corona virus.21 Before SARS-CoV-2, six Covids were known to cause malady in people, including SARS-CoV and MERS-CoV.12 SARS-CoV-2, similar to SARS-CoV and MERS-CoV, is a β-corona virus. The genome arrangement homology of SARS-CoV-2 and SARS is around 79%; SARS-CoV-2 is nearer to the SARS-like bat corona virus (MG772933) than SARS-CoV,13 which slipped from SARS-like bat corona virus. Strangely, a few investigations have demonstrated that SARS-CoV-2 uses angiotension-converting enzyme 2 (ACE2) as its receptor, just the same as SARS-CoV.14 Corona virus essentially perceive their comparing receptors on track cells through S proteins on their surface; section to the phones brings about disease. A structure model examination shows that SARS-CoV-2 ties to ACE2 with more than 10-fold higher partiality than SARS-CoV, at a level over the edge required for virus infection.15 The detail mechanism is by which SARS-CoV-2 infects people by means of authoritative of S-protein to ACE2, the quality of the cooperation for danger of human transmission, and how SARS-CoV-2 causes organ harm stay obscure, and more examinations are required. These outcomes clarify the quicker transmission ability of SARS-CoV-2 in people contrasted and SARS-CoV, and the higher number of affirmed instances of COVID-19 contrasted and SARS-CoV disease. Considering the higher fondness of SARS-CoV-2 official to ACE-2, dissolvable ACE-2 might be a possible contender for the treatment of COVID-19.16

**CLINICAL CHARACTERISTICS OF SARS-COV-2 INFECTION**

SARS-CoV-2 creates an intense viral contamination in people with a middle incubation time of 3 days [17]; this is like SARS-CoV with an incubation time of 2–10 days.18

**MODE OF TRANSMISSION**

Droplets and close contact are the most widely recognized courses of transmission of SARS-CoV-2, and airborne transmission might be another course. Also, scientists have recognized SARS-CoV-2 in tests of stool, gastrointestinal tract, saliva and urine. In view of bioinformatics, proof has demonstrated the digestive tract may be a way of SARS-CoV-2 disease.19 SARS-CoV-2 RNA has been recognized reliably in gastrointestinal tissue from patients with COVID-19.20

In addition, SARS-CoV-2 was recognized in the tears and conjunctival discharges of patients with COVID-19.21 A review investigations of nine pregnant ladies with COVID-19 showed that the chance of intrauterine vertical transmission among moms and babies during late pregnancy was incidentally avoided.22 Be that as it may, accessible information on pregnant ladies tainted with SARS-CoV-2 are insufficient; further examinations are needed to check the chance of vertical transmission of SARS-CoV-2 in pregnant ladies.23

**SYMPTOMS OF CORONA VIRUS (COVID-19)**

**Fever**

Fever is where a human interior warmth level goes over the common extent of 36–37°C (98–100°F) Fahrenheit, It is a commonplace remedial sign. Various articulations for a fever join exact and controlled hyperthermia. As the inside warmth level goes up, the individual may feel cold until it levels off and stops rising.24

**Chills**

The feeling of being cold, nonetheless, not generally in a cool space, routinely joined by welding or shaking.26-27

**Rapid heat beat**

There is no antibody for CoV. To help hinder a Covid ailment, do fundamentally the same as things you do to keep up a key good ways from the typical virus.28

**Breathing difficulties**

There are various purposes behind breathing issues. These normal breathing issues join steady sinusitis, hypersensitivities, and asthma. These issues can cause a huge group of adverse effect,s 29 for instance, nasal blockage, runny nose, disturbed or watery eyes, chest obstruct, hack, wheezing, and worked relaxing.

**Pneumonia**

Pneumonia is an ailment of the lungs with an extent of expected causes. It will in general be an authentic and perilous ailment. It usually starts with a bacterial, viral, or parasitic infection. The lungs become stimulated, and the little air sacs, or alveoli, inside the lungs finish off with fluid [30, 31]. There is no counter acting agent for corona virus. To help hinder a corona virus illness, do fundamentally the same as things you do to keep up a vital good ways from the typical infection: 32-35
• Wash your hands totally with chemical and warm water or with an alcohol based hand sanitizer.
• Keep your hands and fingers from your eyes, nose, and mouth.
• Avoid close contact with people who are defiled.
• You treat a Covid tainting a comparative way you treat an infection:
  • Get a ton of rest
  • Drink fluids
  • Take over-the-counter medicine for an aggravated throat and fever. Notwithstanding, don’t offer cerebral pain medication to adolescents or young people more energetic than use ibuprofen or acetaminophen.
  • A humidifier or hot shower can moreover help encourage a sore and scratchy throat
  • Even when a Covid causes Middle Eastern respiratory condition (MERS) or serious intense respiratory disorder (SARS) in various countries, such a Covid defilement ordinary in the U.S. is authentically not a certified danger for a for the most part stable adult. If you become sick, treat your reactions and contact an expert if they decay or don’t leave.

DIAGNOSIS

A speculate case is characterized as one with fever, sore throat, hack, and trouble in breathing, who has a background marked by movement to China or different regions of persevering neighborhood transmission or contact with patients with comparable travel history or those with affirmed COVID-19 infection. Nonetheless, cases might be asymptomatic or even without fever. An affirmed case is a presume case with a positive molecular test. Explicit finding is by unique analysis atomic test on respiratory examples (oropharyngeal swab/ nasopharyngeal swab/sputum/bronchoalveolar lavage). Infection may likewise be distinguished in the stool and in extreme cases, the blood. In a speculate case in India, the fitting example must be sent to assigned reference labs reserved by the Government of India or the National Institute of Virology in Pune. The white cell tally is normally low. There might be lymphopenia; a lymphocyte check <1000 has been related with extreme sickness. The platelet count is generally typical or somewhat low. The C-responsible protein and erythrocyte sedimentation rate are commonly raised, yet procalcitonin levels are typically ordinary. A high procalcitonin level may demonstrate a bacterial co-disease. The alanine aminotransferase/aspartate aminotransferase, prothrombin time, creatinine D-dimer, creatine phosphokinase, and lactic corrosive dehydrogenase might be raised, and significant levels are related with serious illness. The chest X-beam ordinarily shows reciprocal invades, however might be typical in early infection. Figured tomography (CT) is more sensitive and specific. CT imaging for the most part shows invades, ground glass opacities, and sub-segmental solidification. It is additionally anomalous in asymptomatic patients/patients with no clinical proof of lower respiratory lot association. Truth be told, unusual CT scene have been utilized to analyze COVID-19 in presume cases with negative molecular determination; a considerable lot of these patients had positive sub-molecular tests on repeat testing.37 38

In spite of the fact that the virus (SARS-Cov-2) nucleic acid reverse transcription-polymerase chain reaction (PCR) test has become the standard technique for the conclusion of SARS-CoV-2 disease, these continuous PCR test units have numerous impediments including openness and accessibility issues. There are different serological tests dependent on immunoglobulin M (IgM)/IgG antibody recognition, appropriate for the subjective discovery of CoV (SARS-CoV-2/COVID-19). These incorporate ELISA tests, quick Chromatographic tests and others. IgG antibody by and large starts to ascend inside multi week of beginning infection. IgG shows up around 14 days after infection. Approval measure is in progress in China, Europe, and the USA. The outcomes have been promising with the upsides of quick outcomes, precision (high sensitivity [~89%] and specificity [~93%]), minimal effort, usability, simple availability, quick screening of COVID-19 infection, and so forth.39

TREATMENT OF SARS-COV-2 INFECTION (COVID-19)

Anti-viral Western medical treatment

At present, the treatment of patients with COVID-19 is essentially suggestive. Remdesivir has been accounted for as a promising a tiviral drug against a wide cluster of RNA virus. Holshue et al. revealed that treatment of a patient with COVID-19 with remde-sivir accomplished great outcomes [40]. Xiao et al. discovered that remdesivir was successful in the control of COVID-19 in vitro. Then, chloroquine has been found to have immune modulatory action and could adequately restrain SARS-CoV-2 in vitro.41

Clinical controlled preliminaries have indicated that chloroquine was compelling in the treatment of patients with COVID-19.42 Remdesivir is under-going an enormous number of clinical preliminaries in a few medical clinics; the viability of the medication is dubious at present. Arbidol, a little indole subordinate atom, was found to impede viral combination of influenza A and B viruses and hepatitis C viruses43 and to anti-virally affect SARS-CoV in cell tests 44; all things considered, it might be an opportunities for treatment of patients with COVID-19. A randomized controlled investigation on the treatment of COVID-19 with. Arbidol and Kaletra indicated that Arbidol had a superior remedial impact than Kaletra and could altogether diminish the rate of extreme cases. What’s more, lopinavir/ritonavir, nucleoside analogs, neuraminidase inhibitors, remdesivir and peptide Ek1 could likewise be opportunities for the treatment of COVID-19.45
**Chinese medical treatment**

Chinese medication has additionally assumed a significant part in the treatment of COVID-19. Neighborhood governments and clinical establishments have distributed various conventional Chinese medication remedies. The Novel Corona infection Pneumonia Diagnosis and Treatment Plan (sixth preliminary adaptation) proposed the utilization of a lung clearing and detoxification decoction. A joint report by the Shanghai Institute of Materia Medica and Wuhan Institute of Virology, Chinese Academy of Sciences found that Shuanghuanglian oral fluid could restrain SARS-CoV-2. Past investigations have demonstrated that baicalin, chlorogenic corrosive and forsythin in Shuanghuanglian oral fluid have certain inhibitory consequences for different infections and microorganisms. The mechanism may be that these parts assume a remedial function by adequately decreasing the inflammatory reaction of the body brought about by infections and microscopic organisms. Lianhuqingwen case has been appeared to have a wide-range impact on a progression of flu infections, including H7N9, and could manage the safe reaction of the infection, diminishing the degree of incendiary elements in the beginning phase of disease.

**Immunoenhancement therapy**

One of the pathogenesis of SARS-CoV is brought about by an unbalanced safe reaction. Boosting the body’s resistance is a potential applicant convention for treating SARS patients. Interferons can restrain viral contamination by prompting both inborn and versatile resistant reaction. Engineered recombinant interferon α has been demonstrated to be compelling for the treatment of patients with SARS in clinical preliminaries, the interferon alfacon-1 or more corticosteroids treatment made some shorter memories to half goal of lung radiographic variations from the norm contrasted and corticosteroids treatment alone and was related with diminished sickness related weakened oxygen immersion. Interferon was likewise discovered to be a powerful inhibitor of MERS-CoV replications. These discoveries propose that interferon could be utilized in the treatment of COVID-19. Intravenous immunoglobulin may be the most secure immune-modulator for long haul use in all age groups, and could assist with inhibiting the creation of favorable to provocative cytokines and increment the creation of calming go betweens. Besides, thymosin alpha-1 (Ta1) can be a resistant promoter for patients with SARS, adequately controlling the spread of illness. Intravenous immunoglobulin and Ta1 may likewise be considered for treatment of COVID-19. When there are no adequate immunizations or explicit medications, convalescent plasma treatment could be a viable method to reduce the course of illness for seriously tainted patients. In a ret-forthcoming investigation, healing plasma treatment is more viable than extreme portions of hormonal stun in patients with serious SARS, diminishing mortality and shortening emergency clinic stays. A forthcoming partner concentrate by Hung et al. demonstrated that for patients with pandemic H1N1 influenza virus infection in 2009, the overall danger of death was essentially lower in patients treated with conva-lescent plasma. Also, from the viewpoint of immunology, most patients who recuperate from COVID-19 will create specific antibodies against the SARS-CoV-2, and their serum could be utilized to forestall re-disease. Simultaneously, antibodies can restrict viral generation in the intense period of infection and help clear the infection, which is helpful for quick recuperation from the ailment. Hypothetically, viraemia tops during the principal seven day stretch of most popular contaminations, and it ought to be more compelling to give healing plasma right off the bat in the illness course. Accordingly, the plasma of patients who have recuperated from COVID-19 could be gathered to plan plasma globulin explicit to SARS-CoV-2. In any case, the security of plasma globulin items explicit to SARS-CoV-2 merits further thought.

**Auxiliary blood purification treatment**

At present, extracorporeal blood filtration innovation is utilized in the treatment of patients with extreme NCP. As indicated by the most recent investigation, ACE2, the key receptor of SARS-CoV-2, is profoundly ex-squeezed in human kidney (almost multiple times higher than in lung). Kidney may be the primary objective of assault for SARS-CoV-2. Early ceaseless blood filtration treatment could diminish renal remaining burden and help to advance the recuperation of renal capacity. The most extreme instances of COVID-19 may experience the ill effects of a cytokine storm. The unevenness of favorable to fiery elements and calming variables may cause resistant harm. Thusly, blood purging innovation could be utilized to eliminate provocative components, wipe out cytokine storms, right electrolyte lopsided characteristics and keep up corrosive base equalization to control patients’ ability load in a successful way. 

**PREVENTION OF SARS COV-2/COVID-19**

The CDC prescribes various strides to forestall the transmission and danger of SARS-CoV-2. Successive hand washing enduring at any rate 20 seconds by utilizing cleanser and water is prompted. Hand sanitizers with at any rate 60% liquor can likewise be utilized as another option. General society has likewise been advised to abstain from contacting mucosal surfaces, for example, the mouth and the nose with hands that have not been washed. Anybody indicating side effects of the infection should attempt to look for proper clinical assistance. They ought as far as possible their presentation to other unaffected individuals and spread their noses and mouths when hacking or wheezing. They are additionally encouraged to wear a facemask on the off chance that they present with manifestations. Continuous sterilization and cleaning are prompted for bunches that are in danger of getting the infection.
CONCLUSION
The SARS-CoV-2 is the challenge the world. The Corona virus quickly developing in the greater part of the nations, for example, America, Italy, Spain and India and so on. Since there is not an exact treatment for this infection. In any case, the most ideal approach to forestall yours hand washed with alcohol based hand sanitizer over and over, spread your face with face cover, don’t close contact with infected person, and keep the physical separation multiple meters.

In the present review study, we realize that this virus additionally influence the economic, clinical, and general wellbeing framework of the world.

Acknowledgment: The authors sincerely thank MET faculty of pharmacy, Moradabad, U.P. India, for contributing to this study.

REFERENCES
1. Y. Chen, H. Cai, J. Pan, N. Xiang, P. Tien, T. Ahola, Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase, Proc Natl Acad Sci USA, 106, 2009, 3484-9. 
2. M. Barcena, G.T. Oostergetel, W. Bartelink, Cyo-electron tomography of mouse hepatitis virus: Insights into the structure of the corona virion, Proc Natl Acad Sci U S A, 106, 2009, 582-7. 
3. D.S Hui, E. Azhar, T.A. Madani, F. Ntoumi, R. Kock, O. Dar, The continuing 2019-nCoV epidemic threat of novel coronavirus outbreak to global health, The latest 2019 novel coronavirus outbreak in Wuhan, China, Int J Infect Dis, 91, 2020, 264-6. 
4. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 2020, 497-506
5. Available from: http://www.worldometers.info, [Last accessed on 2020 Apr 1].
6. 2019 Novel Coronavirus virus (2019-nCoV), Centers for Disease Control and Prevention, Available from: https://www.cdc.gov/coronavirus/2019-ncov/index.html, [Last accessed as on 2020 Mar 22].
7. D.D. Richman, R.J. Whitley, F.G. Hayden, Clinical Virology, 4th edition, Washington: ASM Press, 2016.
8. M. Chan-Yeung, R.H. Xu, SARS: epidemiology, Respirology, 2003, 8, 59–14.
9. Middle East Respiratory Syndrome coronavirus. Available at: https://www.who.int/emergencies/mers-cov/en/. [Accessed, 16 Feb 2020].
10. WHO: coronavirus disease (COVID-2019) situation reports. (2020).: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. [Accessed: March 11, 2020]
11. J.F. Chan, K.K. To, H. Tse, D.Y. Jin, K.Y. Yuen, Interspecies transmission and emergence of novel viruses: lessons from bats and birds, Trends Microbiol, 21, 2013, 544–55.
12. N. Zhu , D. Zhang , W. Wang , X. Li , B. Yang , J. Song , et al, A novel coronavirus from patients with pneumonia in China, 2019, New England Journal of Med, 382(8), 2020, 727–33.
13. A. Wu, Y. Peng , B. Huang , X. Ding, X. Wang, P. Niu, Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China, Cell Host Microbe 27(3), 2020, 325–8.
14. M. Hoffmann, H. Kleine-Weber, N. Kruger, M. Muller, C. Drosten, S. Pohlmann, The novel coronavirus 2019 (2019-nCoV) uses the SARS-corona virus receptor ACE2 and the cellular pro tease TMPRSS2 for entry into target cells, BioRxiv, 2020, 2020.01.31.929042.
15. D. Wrapp , N. Wang , K.S. Corbett, J.A. Goldsmith C.L. Hsieh , O. Abiona, Cryo- EM structure of the 2019-nCoV spike in the prefusion conformation, Science (New York, NY367 (6483), 2020, 1260-3.
16. J. Remais, Modelling environmentally-mediated infectious diseases of humans: transmission dynamics of schistosomiasis in China, Adv Exp Med Biol, 673, 2010, 79–98.
17. W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, Clinical characteristics of 2019 novel coronavirus infection in China, Engl J Med, 2020, doi: 10.1056/NEJMoa2002032.
18. P.K. Chan, J.W. Tang, D.S. Hui, SARS: clinical presentation, transmission, pathogenesis and treatment options, Clinical Science, 110, 2006, 193–204.
19. J. Wang, S. Zhao, M. Liu, Z. Zhao, Y. Xu, P. Wang, ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism, MedRxiv, 2020; 2020.02.05.20020545.
20. F. Xiao, M. Tang, X. Zheng, C. Li, J. He, Z. Hong, Evidence for gastrointestinal infection of SARS-CoV-2, MedRxiv, 2020; 2020.02.17.20023721.
21. J. Xia, J. Tong, M. Liu, Y. Shen, D. Guo, Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection, J Med Virol, 2020. doi: 10.1002/jmv.25725.
22. H. Chen, J. Guo, C. Wang, F. Luo, X. Yu, W. Zhang, Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet, 395(10226), 2020, 809–15.
23. K.R. Hurst, C.A. Koetzner, P.S. Masters, Characterization of a critical interaction between the coronavirus nucleocapsid protein and nonstructural protein 3 of the viral replicase transcriptase complex, J Virol, 87, 2013, 9159-72.
24. L.S. Sturman, K.V. Holmes J. Behnke, Isolation of SARS coronavirus envelope glycoproteins and interaction with the viral nucleocapsid, J Virol, 33, 1980, 449–62.
25. A. Klaussegger, B. Strobi, G. Reigl, A. Kaser, W. Luytjes, R. Vlasak, Identification of a coronavirus hemagglutinin esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. J Virol, 73, 1999, 3737–43.
26. L.A. Cornelissen, C.M. Wierda, F.J. van der Meer, A.A. Herrewegh, M.C. Horzinek, H.F. Egberink, Hemagglutinin-esterase, a novel structural protein of torovirus. J Virol, 71, 1997, 5277-86.
27. L. Kazi, A. Lissenberg, R. Watson, R.J. Groot, S.R. Weiss, Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence, J Virol, 79, 2005, 15064–73.
28. A. Lissenberg, M.M. Vrolijk, A.L. van Vliet, M.A. Langereis, J.D. de Groot-Mijnes, P.J. Rottier, Luxury at a cost recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro, J Virol, 79, 2005, 15064-53.
29. P.K. Cheng, D.A. Wong, L.K. Tong, C.S. Lau, E.Y. Yeung, W.W. Lim WW, Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome, Lancet, 363, 2004, 1699-700.
30. S. Belouzard, V.C. Chu, G.R. Whittaker, Activation of the SARS coronavirus spike virus protein via sequential proteolytic cleavage at two distinct sites, Proc Natl Acad Sci USA, 106, 20095871-6.
31. P.V. Baranov, C.M. Henderson, C.B. Anderson, F.F. Gesteland, J.F. Atkins, M.T. Howard MT, Programmed ribosomal frame shifting in decoding the SARS-CoV genome, Virology, 332, 2005, 498-510.
32. Brierley, P. Digard, S.C. Inglis, Characterization of an efficient coronavirus ribosomal frame shifting signal: Requirement for an RNA pseudoknot Cell, 57, 1989, 537-47.
33. K. Araki, S. Gangappa, D.L. Dillehay, B.T. Rouse, C.P. Larsen, R. Ahmed, Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: Implications for transplantation, J Exp Med, 207, 2010, 2355-67.
47. N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study, Lancet, 395, 2020, 507-13.

48. X.W. Xu, X.X. Wu, X.G. Jiang, K.X. Ju, L.J. Ying, C.L Ma, Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series, BMJ, 68, 2020, m606.

49. P. Huang, T. Liu, L. Huang, H. Liu, M. Lei, W. Xu, Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion, Radiology, 295, 2020, 295:22-3.

50. M.L. Holshu, C. DeBolt, S. Lindquist, K.H. Lofy, J. Wiesman, H. Bruce, First case of 2019 novel coronavirus in the United States, N Engl J Med, 382(10), 2020; 929–36.

51. M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, 30(3), 2020; 269–71.

52. J. Gao, Z. Tian, X. Yang: Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 14(1), 2020, 72–3.

53. Y.S. Borisik, I.A Leneva, E.I. Pecheur, S.J. Poljak, Arbidol: a broad-spectrum antiviral compound that blocks viral fusion, Curr Med Chem, 15, 2008, 997–1005.

54. K.A. Khamitov, S. Loginova, V.N. Shchukina, S.V. Borisевич, V.A Maksimov, A.M. Shus-ter, [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures], Vopr Virusol, 53, 2008, 9–13.

55. H. Lu, Drug treatment options for the 2019-novel coronavirus (2019-nCoV). Biosci Trends, 14(1), 2020, 69–71.

56. China National health commission, The novel coronavirus pneumonia diagnosis and treatment plan (6th trial version), 2020.

57. W. Li, The curative effect observation of shuanghuanglian and penicillin on acute tonsillitis, Lin Chuang Er Bi Yan Hou Ke Za Zhi, 16, 2002; 475–6.

58. H.T. Lu, J.C. Yang, Z.C. Yuan, W.H. Sheng, W.H. Yan WH, [Effect of combined treatment of Shuanghuanglian and recombinant interferon alpha 2a on coxsackie virus B3 replication in vitro], Zhongguo Zhong Yao Za Zhi, 25, 2000, 682–4.

59. X. Chen, O.M. Howard, X. Yang, L. Wang, J.J. Oppenheim, T. Krakauer, Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function, Life Sci, 70, 2002, 2897-913.

60. J. Ziebuhr, E.J. Snijder, A.E. Gorbalenya, Virus-encoded proteinases and proteolytic processing in the Nidovirales, J Gen Virol, 81, 2000, 853-79.

61. J.E. Snijder, P.J. Bredenbeek, J.C. Dobbe, V. Thiell, J. Ziebuhr, L.L.L Poon, Unique and conserved features of genome and proteome of SARS-corona virus, an early split-off from the corona virus group 2 lineage, J Mol Biol, 331, 2003, 991-1004.

62. N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China, Int. J. Pharm. Sci., 2020; 475.

63. Maksimov, A.M. Shus-ter, [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures], J Gen Virol, 81, 2000, 991-1004.

64. A.M. Sainovitch, S. Ward, B. Wolff, H. Lho, Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study, JAMA, 290, 2003, 3222-8.

65. S. Mustafa, H. Balkhy, M.N. Gabere, Current treatment options and the role of peptides as potential therapeutic components for Middle East respiratory syndrome (MERS): a review, J Infect Public Health, 11, 2018, 9–17.

66. L. Gildain, J. Bayry, S.V. Kaveri, Intravenous immunoglobulin as clinical immune-modulating therapy, CMAJ, 187, 2015, 257–64.

67. V. Kumar, Y.S. Jung, P.L. Liang, Anti-SARS coronavirus agents: a patent review (2008–present), Expert Opin Ther Pat, 23, 2013, 1337–48.

68. J. Mair-Jenkins, M. Saavedra-Campos, J.K. Baillie, P. Cleary, F.M. Khaw, W.S. Lim, The effectiveness of convalescent plasma and hyper immune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis, 211, 2015, 80–90.

69. Y.O. Soo, Y. Cheng, R. Wong, D.D. Hui, C.K. Lee, K.K. Tsang, Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients, Clin Microbiol Infect, 10, 2004, 676–8.

70. I.F. Hung, K.K. T, C.K. Lee, K.L. Lee, K. Chan, W.W. Yan, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin Infect Dis, 52, 2011, 447–56.

71. S. Baron, editor, Medical microbiology, 4th edition, Galveston, TX: University of Texas Medical Branch, 1996.

72. Y. Cheng, R. Wong, Y.O. Soo, W.S. Wong, C.K. Lee, M.H. Ng, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, 24, 2005, 447–52.

73. A. Zarbock, J.A. Kellum, C. Schmidt, H. Van Aken, C. Wempe, H. Parent, Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial, JAMA, 315, 2016, 4190–9.

74. C.C. Lim, C.S. Tan, M. Kaushik, H.K. Tan, Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study, Nephrol, 20, 2015, 148–54.

75. Centers for Disease Control and Prevention: corona virus disease 2019 (COVID-19) - how to protect yourself. (2020), Accessed: March 11, 2020: https://www.cdc.gov/coronavirus/2019-ncov/about/prevention.html.

76. K. Ramphul, S.G. Mejias (March 15, 2020) Corona virus Disease: A Review of a New Threat to Public Health, Cureus, 12(3), e7276, DOI 10.7759/cureus.